Total Payments
$381,124
2024 Payments
$1,183
Companies
32
Transactions
844
Medicare Patients
2,410
Medicare Billing
$117,769
Payment Breakdown by Category
Other$269,016 (70.6%)
Consulting$61,372 (16.1%)
Travel$33,029 (8.7%)
Food & Beverage$16,452 (4.3%)
Research$982.02 (0.3%)
Education$272.39 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $269,016 | 126 | 70.6% |
| Consulting Fee | $61,372 | 22 | 16.1% |
| Travel and Lodging | $33,029 | 161 | 8.7% |
| Food and Beverage | $16,452 | 518 | 4.3% |
| Unspecified | $982.02 | 9 | 0.3% |
| Education | $272.39 | 8 | 0.1% |
Payments by Type
General
$380,142
835 transactions
Research
$982.02
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $141,610 | 318 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $107,124 | 171 | $0 (2023) |
| GlaxoSmithKline, LLC. | $81,942 | 172 | $0 (2024) |
| Circassia Pharmaceuticals Inc | $14,180 | 24 | $0 (2018) |
| Genentech USA, Inc. | $10,554 | 19 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $7,912 | 11 | $0 (2020) |
| Regeneron Pharmaceuticals, Inc. | $7,139 | 12 | $0 (2022) |
| Teva Pharmaceuticals USA, Inc. | $5,671 | 34 | $0 (2023) |
| Amgen Inc. | $1,973 | 12 | $0 (2023) |
| AstraZeneca UK Limited | $1,359 | 2 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,183 | 51 | AstraZeneca Pharmaceuticals LP ($280.44) |
| 2023 | $592.81 | 32 | GlaxoSmithKline, LLC. ($208.56) |
| 2022 | $706.64 | 21 | AstraZeneca Pharmaceuticals LP ($286.63) |
| 2021 | $46,148 | 69 | AstraZeneca Pharmaceuticals LP ($22,551) |
| 2020 | $23,588 | 41 | GlaxoSmithKline, LLC. ($16,956) |
| 2019 | $118,146 | 217 | AstraZeneca Pharmaceuticals LP ($50,112) |
| 2018 | $108,287 | 248 | AstraZeneca Pharmaceuticals LP ($57,476) |
| 2017 | $82,471 | 165 | Boehringer Ingelheim Pharmaceuticals, Inc. ($51,001) |
All Payment Transactions
844 individual payment records from CMS Open Payments — Page 1 of 34
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $14.86 | General |
| Category: Respiratory | ||||||
| 12/10/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $35.44 | General |
| Category: Immunology | ||||||
| 12/05/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $25.37 | General |
| Category: Immunology | ||||||
| 12/03/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $21.33 | General |
| Category: Respiratory | ||||||
| 11/21/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $20.84 | General |
| Category: RESPIRATORY | ||||||
| 11/14/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $14.59 | General |
| Category: Respiratory | ||||||
| 10/31/2024 | Grifols USA, LLC | Prolastin-C Liquid (Biological) | Food and Beverage | In-kind items and services | $24.20 | General |
| Category: Pulmonology | ||||||
| 10/29/2024 | Merck Sharp & Dohme LLC | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $16.24 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/17/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $20.47 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 10/10/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $14.59 | General |
| Category: Respiratory | ||||||
| 10/03/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $25.87 | General |
| Category: Immunology | ||||||
| 09/26/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $28.10 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/26/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $22.44 | General |
| Category: Respiratory | ||||||
| 09/19/2024 | Grifols USA, LLC | Prolastin-C Liquid (Biological) | Food and Beverage | In-kind items and services | $24.96 | General |
| Category: Pulmonology | ||||||
| 09/18/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $27.91 | General |
| Category: Respiratory | ||||||
| 09/17/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $14.25 | General |
| Category: Respiratory | ||||||
| 08/22/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $16.78 | General |
| Category: IMMUNOLOGY | ||||||
| 08/15/2024 | Merck Sharp & Dohme LLC | ZERBAXA (Drug), RECARBRIO | Food and Beverage | In-kind items and services | $24.37 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 08/13/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $20.84 | General |
| Category: RESPIRATORY | ||||||
| 08/08/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $23.56 | General |
| Category: Respiratory | ||||||
| 08/06/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $15.54 | General |
| Category: Respiratory | ||||||
| 07/30/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $17.63 | General |
| Category: IMMUNOLOGY | ||||||
| 07/25/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $20.84 | General |
| Category: RESPIRATORY | ||||||
| 07/18/2024 | Vifor Pharma, Inc. | Zemaira (Drug) | Food and Beverage | In-kind items and services | $21.88 | General |
| Category: Pulmonary/Respiratory Diseases | ||||||
| 07/15/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $26.95 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 590 | 758 | $96,398 | $26,369 |
| 2022 | 9 | 547 | 710 | $79,021 | $26,993 |
| 2021 | 8 | 570 | 768 | $82,572 | $32,667 |
| 2020 | 11 | 703 | 883 | $94,891 | $31,741 |
Total Patients
2,410
Total Services
3,119
Medicare Billing
$117,769
Procedure Codes
38
All Medicare Procedures & Services
38 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 154 | 213 | $50,741 | $15,062 | 29.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 29 | 34 | $11,401 | $3,684 | 32.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 16 | 16 | $6,551 | $2,272 | 34.7% |
| 94621 | Test for exercise-induced heart and lung stress | Facility | 2023 | 30 | 30 | $7,527 | $1,536 | 20.4% |
| 94010 | Test to measure expiratory airflow and volume | Facility | 2023 | 161 | 235 | $7,217 | $1,433 | 19.9% |
| 94618 | Test for exercise-induced lung stress | Facility | 2023 | 39 | 52 | $4,227 | $886.89 | 21.0% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2023 | 68 | 80 | $2,593 | $549.05 | 21.2% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Facility | 2023 | 48 | 51 | $1,911 | $388.06 | 20.3% |
| 94726 | Test to determine lung volumes using sensors | Facility | 2023 | 34 | 35 | $1,533 | $318.92 | 20.8% |
| 94070 | Test to measure lung airway sensitivity | Facility | 2023 | 11 | 12 | $2,695 | $239.03 | 8.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 139 | 191 | $36,836 | $13,739 | 37.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 35 | 46 | $12,173 | $4,700 | 38.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 21 | 21 | $7,727 | $2,948 | 38.1% |
| 94621 | Test for exercise-induced heart and lung stress | Facility | 2022 | 48 | 49 | $9,889 | $2,496 | 25.2% |
| 94010 | Test to measure expiratory airflow and volume | Facility | 2022 | 169 | 246 | $5,888 | $1,487 | 25.2% |
| 94618 | Test for exercise-induced lung stress | Facility | 2022 | 37 | 49 | $3,181 | $833.96 | 26.2% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Facility | 2022 | 39 | 43 | $1,495 | $329.92 | 22.1% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2022 | 43 | 48 | $1,202 | $316.49 | 26.3% |
| 94726 | Test to determine lung volumes using sensors | Facility | 2022 | 16 | 17 | $629.48 | $142.33 | 22.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 167 | 247 | $41,990 | $17,750 | 42.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 53 | 63 | $15,435 | $6,923 | 44.9% |
| 94621 | Test for exercise-induced heart and lung stress | Facility | 2021 | 51 | 51 | $9,078 | $2,687 | 29.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 15 | 15 | $5,325 | $2,232 | 41.9% |
| 94010 | Measurement and graphic recording of total and timed exhaled air capacity | Facility | 2021 | 189 | 288 | $6,344 | $1,823 | 28.7% |
| 94618 | Test for exercise-induced lung stress | Facility | 2021 | 41 | 48 | $2,948 | $841.80 | 28.6% |
About Dr. Mark Millard, M.D
Dr. Mark Millard, M.D is a Pulmonary Disease healthcare provider based in Dallas, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/10/2005. The National Provider Identifier (NPI) number assigned to this provider is 1609877737.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Millard, M.D has received a total of $381,124 in payments from pharmaceutical and medical device companies, with $1,183 received in 2024. These payments were reported across 844 transactions from 32 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($269,016).
As a Medicare-enrolled provider, Millard has provided services to 2,410 Medicare beneficiaries, totaling 3,119 services with total Medicare billing of $117,769. Data is available for 4 years (2020–2023), covering 38 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Dallas, TX
- Active Since 08/10/2005
- Last Updated 07/05/2023
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1609877737
Products in Payments
- FASENRA (Drug) $106,812
- TRELEGY ELLIPTA (Drug) $47,794
- SPIRIVA RESPIMAT (Drug) $30,054
- ANORO (Drug) $19,542
- NIOX VERO DEVICE (Device) $14,079
- Xolair (Biological) $10,491
- FASENRA (Biological) $10,294
- SPIRIVA (Drug) $7,065
- DUPIXENT DUPILUMAB INJECTION (Biological) $7,044
- OFEV (Drug) $4,607
- STIOLTO RESPIMAT (Drug) $3,626
- ProAir Digihaler (Drug) $3,401
- ArmonAir Digihaler (Drug) $1,916
- DUPIXENT (Biological) $652.16
- NUCALA (Biological) $483.80
- ANORO ELLIPTA (Drug) $341.95
- BEVESPI AEROSPHERE (Drug) $245.61
- SYMBICORT (Drug) $214.51
- TEZSPIRE (Biological) $185.51
- STIOLTO (Drug) $139.92
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Dallas
Dr. Fernando Torres, M.d, M.D
Pulmonary Disease — Payments: $247,706
Pulmonary Disease $247,706
Dr. Raksha Jain, Md, MD
Pulmonary Disease — Payments: $189,093
Pulmonary Disease $189,093
Dr. Kelly Chin, M.d, M.D
Pulmonary Disease — Payments: $103,886
Pulmonary Disease $103,886
Dr. Gary Weinstein, M.d, M.D
Pulmonary Disease — Payments: $102,068
Pulmonary Disease $102,068
Anthony Ortegon, Md, MD
Pulmonary Disease — Payments: $95,730
Pulmonary Disease $95,730
Dr. Abhishek Kumar, M.d, M.D
Pulmonary Disease — Payments: $47,973
Pulmonary Disease $47,973